Table 1.
Patient and graft characteristics according to presence of HLA-antibodies (n = 82).
| Characteristics | Total | No Antibody | Antibody | p value |
|---|---|---|---|---|
|
| ||||
| N of patients | 82 | 54 (66%) | 28 (34%) | |
|
| ||||
| Median (range) age, years | 48 (2–69) | 48 (2–69) | 49 (10–64) | 0.53 |
|
| ||||
| Median (range) weight, kg | 70 (15–125) | 76 (15–125) | 67 (37–93) | 0.09 |
|
| ||||
| Gender, n (%) female | 34 (41%) | 14 (26%) | 20 (71%) | < 0.01 |
|
| ||||
| Diagnosis, n (%) | 0.06 | |||
| AML | 33 (40%) | 17 (31%) | 16 (57%) | |
| ALL | 14 (17%) | 9 (17% ) | 5 (18%) | |
| MDS & MPD | 9 (11%) | 6 (11%) | 3 (11%) | |
| Lymphoma & CLL | 26 (32%)3 | 22 (41%)3 | 4 (14%)3 | |
|
| ||||
| Recipient CMV+ | 47 (57%) | 26 (48%) | 21 (78%) | 0.03 |
|
| ||||
| Conditioning, n (%) | ||||
| High dose myeloablative | 21 (26%) | 12 (22%) | 9 (32%) | 0.16 |
| Reduced intensity* | 46 (56%) | 29 (54%) | 17 (61%) | |
| Non-myeloablative | 15 (18%) | 13 (24%) | 2 (7%) | |
|
| ||||
| Number of units | 164 | 108 | 56 | |
|
| ||||
| Unit-recipient HLA-A, -B antigen, -DRB1 allele match | ||||
| 6/6 | 7 (4%) | 4 (4%) | 3 (5%) | 0.12 |
| 5/6 | 78 (48%) | 45 (42%) | 33 (59%) | |
| 4/6 | 79 (48%) | 59 (55%) | 20 (36%) | |
|
| ||||
| Inf. TNC × 107/kg | ||||
| Larger | 2.9 (1.5–5.6) | 2.9 (1.5–5.6) | 2.9 (1.5–5.5) | 0.73 |
| Smaller | 2.0 (1.1–4.5) | 2.0 (1.4–4.5) | 2.0 (1.1–2.8) | 0.46 |
| Inf. CD34+ cell × 105/kg | ||||
| Larger | 1.4 (0.3–4.5) | 1.5 (0.3–4.5) | 1.3 (0.4–3.0) | 0.22 |
| Smaller | 0.7 (0.2–1.6) | 0.7 (0.2–1.6) | 0.6 (0.2–1.5) | 0.43 |
N indicates number; kg, kilogram; AML, acute myeloid leukemia; ALL, acute lymphoblastic leukemia; MDS, myelodysplastic syndrome; MPD, myeloproliferative disorder; CLL, chronic lymphocytic leukemia; CMV, cytomegalovirus; Inf, infused; TNC, total nucleated cells.
*
Reduced intensity conditioning was predominantly Cy 50/ Flu 150/ Thio 10/ TBI 400 in 44/46 patients. This regimen is functionally myeloablative.